Cargando…
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%–15%) or relapsing-remitting (85%–90%) course. The pathological hallmarks of MS are lesions of both white and grey matter in the central nervous system. The onset of the disease is usually around...
Autor principal: | Jankovic, Slobodan M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218739/ https://www.ncbi.nlm.nih.gov/pubmed/22096354 |
Ejemplares similares
-
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009) -
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015) -
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017) -
Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
por: Marziniak, Martin, et al.
Publicado: (2014) -
Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?
por: Clapin, Alexis
Publicado: (2012)